US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.130 -0.060 (-5.04%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of American Eagle Outfitters, Inc. (NYSE: AEO) declined during Tuesday’s session after the company reported third-quarter financial results. Net revenue rose 5% Y/Y to $1.30 billion, beating the... 
Via Benzinga
News headline image
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
These Apple Insiders Are Selling Shares of AAPL Stock ↗
Apple stock is on the move Wednesday after several insiders at the company, including CEO Tim Cook, sold shares of AAPL. 
Via InvestorPlace
News headline image
Why Is Nvni Group (NVNI) Stock Down 8% Today? ↗
Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger. 
Via InvestorPlace
News headline image
Why Is Gain Therapeutics (GANX) Stock Moving Today? ↗
Gain Therapeutics stock is on the move Wednesday as investors in GANX react to updated clinical trial news from the company. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. 
Via InvestorPlace
News headline image
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
First small molecule allosteric binder discovered with Gain’s computational drug discovery platform enters clinical development 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023 ↗
 
Via Benzinga
News headline image
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
Via Get News
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
--News Direct-- 
Via News Direct
Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research
Bethesda, MD, August 29, 2023 (PlatoData via 500NewsWire) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies,... 
Via TheNewswire.com
News headline image
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >